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PROCEEDINGS
diagnosed with diabetes. Clearly, the combination of in 
and outpatient data provides benefits to estimating preva-
lence and incidence rates. Compared to the results from 
outpatient billing data of Germany’s Associations of 
Statutory Health Insurance Physicians, the analysis of 
DaTraV data shows higher estimates of diabetes preva-
lence because the data provide a more realistic picture of 
actual health care provision. By enabling population-wide 
estimates on disease frequency, DaTraV data importantly 
contributes to the further development of health report-
ing. Federal health reporting (GBE) at the Robert Koch 
Institute is involved in the permanent development of 
this information system. It actively participates in the 
health care data provision working group of Germany’s 
umbrella organisation for networked medical research 
TMF e.V. Moreover, in co-operation with DIMDI, it devel-
ops standard analyses that represent a key element in the 
establishment of a routine provision of DaTraV data for 
health reporting and surveillance.
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Since 2014, claims data of statutory health insurance com-
panies in Germany, which provides a basis to calculate 
the morbidity-oriented risk structure compensation 
scheme (Morbi-RSA), can be analysed by certain institu-
tions for defined purposes. Book 5 of the German Social 
Code sections 303a et seq. as well as Germany’s Data 
Transparency Regulations (DaTraV) sets the details out 
more clearly. DaTraV applies to the data of all statutorily 
insured persons in Germany, and access to this data can 
be applied for at the German Institute of Medical Docu-
mentation and Information (DIMDI) for specific ques-
tions. The data set contains information on outpatient 
and inpatient care, costs and prescribed medications. 
Potentially this data could allow estimates on prevalence 
and incidence rates based on the data of roughly 70 mil-
lion statutorily insured. One limitation is the scope of this 
data, as it only includes part of all claims data (excluding 
for example data on long-term care insurance). Moreover, 
it currently takes four years from data collection to data 
provision, after which those wishing to access the data 
still need to go through a lengthy application process. 
After the first phase of incoming data applications the 
procedures have been internally evaluated resulting in a 
current revision of DaTraV with regard to making access 
to data easier and speeding up the application process. 
An initial analysis in the context of diabetes surveillance 
at the Robert Koch Institute indicates that roughly one in 
seven publicly insured patients aged over 40 has been 
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